- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Alembic Pharmaceuticals has announced a board meeting to approve the financial results for the quarter and half-year. Consolidated total income grew to ₹1,769.64 Cr from ₹1,516.98 Cr year-on-year, while net profit after tax attributable to shareholders declined to ₹156.89 Cr from ₹178.21 Cr. Standalone income rose to ₹1,570.64 Cr, but profit after tax dropped to ₹75.34 Cr. The company shows steady revenue growth but faces pressure on standalone profitability, signaling mixed operational performance for shareholders.